VIATRIS INC. Increase (Decrease) in Income Taxes Payable
VIATRIS INC. (VTRS) reported Increase (Decrease) in Income Taxes Payable of -$422.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable · last filed 2026-08-06
- VIATRIS INC. increase (decrease) in income taxes payable for the quarter ending 2026-06-30 was $40.90M.
- VIATRIS INC. increase (decrease) in income taxes payable for the quarter ending 2026-03-31 was -$463.40M.
- VIATRIS INC. increase (decrease) in income taxes payable for the quarter ending 2025-12-31 was $125.50M.
- VIATRIS INC. increase (decrease) in income taxes payable for the quarter ending 2025-09-30 was $128.20M, a 52.20% decline year-over-year.
- VIATRIS INC. increase (decrease) in income taxes payable for fiscal 2025 was -$112.90M, a 151.48% decline from fiscal 2024.
- VIATRIS INC. increase (decrease) in income taxes payable for fiscal 2024 was $219.30M.
- VIATRIS INC. increase (decrease) in income taxes payable for fiscal 2023 was -$76.70M, a 403.16% decline from fiscal 2022.
- VIATRIS INC. increase (decrease) in income taxes payable for fiscal 2022 was $25.30M.
| Period end | Increase (Decrease) in Income Taxes Payable 3 month | Increase (Decrease) in Income Taxes Payable 6 month | Increase (Decrease) in Income Taxes Payable 9 month | Increase (Decrease) in Income Taxes Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $40.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$422.50M 10-Q · filed 2026-08-06 | -$297.00M derived: sum of 3 quarters · filed 2026-08-06 | -$168.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$463.40M 10-Q · filed 2026-05-07 | -$337.90M derived: sum of 2 quarters · filed 2026-05-07 | -$209.70M derived: sum of 3 quarters · filed 2026-05-07 | -$455.70M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $125.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $253.70M derived: sum of 2 quarters · filed 2026-02-26 | $7.70M derived: sum of 3 quarters · filed 2026-08-06 | -$112.90M 10-K · filed 2026-02-26 |
| 2025-09-30 | $128.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$117.80M derived: sum of 2 quarters · filed 2026-08-06 | -$238.40M 10-Q · filed 2025-11-06 | -$306.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$246.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$366.60M 10-Q · filed 2026-08-06 | -$434.20M derived: sum of 3 quarters · filed 2026-08-06 | -$166.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$120.60M 10-Q · filed 2026-05-07 | -$188.20M derived: sum of 2 quarters · filed 2026-05-07 | $80.00M derived: sum of 3 quarters · filed 2026-05-07 | $101.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$67.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $200.60M derived: sum of 2 quarters · filed 2026-02-26 | $221.60M derived: sum of 3 quarters · filed 2026-02-26 | $219.30M 10-K · filed 2026-02-26 |
| 2024-09-30 | $268.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $289.20M derived: sum of 2 quarters · filed 2025-11-06 | $286.90M 10-Q · filed 2025-11-06 | $239.80M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $21.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $18.70M 10-Q · filed 2025-08-07 | -$28.40M derived: sum of 3 quarters · filed 2026-02-26 | -$35.90M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$2.30M 10-Q · filed 2025-05-08 | -$49.40M derived: sum of 2 quarters · filed 2026-02-26 | -$56.90M derived: sum of 3 quarters · filed 2026-02-26 | -$25.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$47.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$54.60M derived: sum of 2 quarters · filed 2026-02-26 | -$22.80M derived: sum of 3 quarters · filed 2026-02-26 | -$76.70M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$7.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $24.30M derived: sum of 2 quarters · filed 2024-11-07 | -$29.60M 10-Q · filed 2024-11-07 | -$33.80M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $31.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$22.10M 10-Q · filed 2024-08-08 | -$26.30M derived: sum of 3 quarters · filed 2025-02-27 | -$14.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$53.90M 10-Q · filed 2024-05-09 | -$58.10M derived: sum of 2 quarters · filed 2025-02-27 | -$46.40M derived: sum of 3 quarters · filed 2025-02-27 | -$95.60M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$4.20M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.50M derived: sum of 2 quarters · filed 2025-02-27 | -$41.70M derived: sum of 3 quarters · filed 2025-02-27 | $25.30M 10-K · filed 2025-02-27 |
| 2022-09-30 | $11.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$37.50M derived: sum of 2 quarters · filed 2023-11-08 | $29.50M 10-Q · filed 2023-11-08 | $5.20M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$49.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $17.80M 10-Q · filed 2023-08-07 | -$6.50M derived: sum of 3 quarters · filed 2024-02-28 | -$344.10M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $67.00M 10-Q · filed 2023-05-08 | $42.70M derived: sum of 2 quarters · filed 2024-02-28 | -$294.90M derived: sum of 3 quarters · filed 2024-02-28 | -$1.13B derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$24.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$361.90M derived: sum of 2 quarters · filed 2024-02-28 | -$1.19B derived: sum of 3 quarters · filed 2024-02-28 | -$699.60M 10-K · filed 2024-02-28 |
| 2021-09-30 | -$337.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$1.17B derived: sum of 2 quarters · filed 2022-11-07 | -$675.30M 10-Q · filed 2022-11-07 | -$786.90M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$832.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$337.70M 10-Q · filed 2022-08-08 | -$449.30M derived: sum of 3 quarters · filed 2023-02-27 | -$383.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $494.60M 10-Q · filed 2022-05-09 | $383.00M derived: sum of 2 quarters · filed 2023-02-27 | $448.90M derived: sum of 3 quarters · filed 2023-02-27 | $487.40M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$111.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$45.70M derived: sum of 2 quarters · filed 2023-02-27 | -$7.20M derived: sum of 3 quarters · filed 2023-02-27 | $3.60M 10-K · filed 2023-02-27 |
| 2020-09-30 | $65.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $104.40M derived: sum of 2 quarters · filed 2021-11-08 | $115.20M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $38.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $49.30M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | $10.80M 10-Q · filed 2021-05-10 | |||
| 2019-12-31 | $57.90M 10-K · filed 2022-02-28 | |||
| 2018-12-31 | -$23.90M 10-K · filed 2021-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |